P086: Non-enzymatic serum antioxidant capacity is diminished in inflammatory bowel disease and is associated with severity of inflammation in ulcerative colitisECCO '18 Vienna
2018
P087: A novel OGR1 (GPR68) inhibitor attenuates inflammation in a murine model of Acute ColitisECCO '18 Vienna
2018
P088: Mucosal CD103+ CD4+ and CD103+CD8+ T-cell subsets in the gut of inflammatory bowel disease patients at diagnosis and during follow-upECCO '18 Vienna
2018
P089: Adalimumab and infliximab biosimilar ameliorated cachexic syndrome of Crohn DiseaseECCO '18 Vienna
2018
P090: Is Epstein–Barr virus infection associated with the pathogenesis of microscopic colitis?ECCO '18 Vienna
2018
P091: Inflammation in relation to mucosal barrier function in chronic colitis: a study in timeECCO '18 Vienna
2018
P093: CCL20 and CCR6 on peripheral blood mononuclear cells (PBMC) in inflammatory bowel disease (IBD): a more potent chemokine in ulcerative colitis?ECCO '18 Vienna
2018
P095: Consequences of an IL2RA locus duplication in a very early onset inflammatory bowel disease patientECCO '18 Vienna
2018
P096: Failure to control inflammation as a driving force of symptoms and phenotype in the NSG mouse model of ulcerative colitis.ECCO '18 Vienna
2018
P097: BJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analogue, ameliorates DSS-induced colitis in miceECCO '18 Vienna
2018
P098: Aryl hydrocarbon receptor ameliorates intestinal barrier dysfunction in colitis by regulating the myosin light-chain kinase signalling pathwayECCO '18 Vienna
2018
P099: Postprandial intestinal motility and related physiology in active small-bowel Crohn’s diseaseECCO '18 Vienna
2018
P100: Guanosine prevents nuclear factor-κB nuclear translocation ameliorating experimental colitis in ratsECCO '18 Vienna
2018
P102: Increased abundance of gut microbial virulence genes and pro-inflammatory pathways during Crohn’s disease exacerbationsECCO '18 Vienna
2018